Where do your current and future priorities lie in the biosimilar quality-by-design process?
We posed this question to the industry and the results are in;
- the top priority when companies are looking to apply QbD to their biosimilar production is physiochemical characterisation
- a close second are biological characterisations
- and closing off the top three are preclinical concerns
What are your top priorities when it comes to QbD?
Interested in reading more on this topic? Take a look here:
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D